Yi PS, Zhang M, Zhao JT, Xu MQ. Liver resection for intermediate hepatocellular carcinoma. World J Hepatol 2016; 8(14): 607-615 [PMID: 27190577 DOI: 10.4254/wjh.v8.i14.607]
Corresponding Author of This Article
Ming-Qing Xu, MD, Department of Liver Surgery, West China Hospital, Sichuan University, Guoxue Road, Chengdu 610041, Sichuan Province, China. xumingqing0018@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. May 18, 2016; 8(14): 607-615 Published online May 18, 2016. doi: 10.4254/wjh.v8.i14.607
Liver resection for intermediate hepatocellular carcinoma
Peng-Sheng Yi, Ming Zhang, Ji-Tong Zhao, Ming-Qing Xu
Peng-Sheng Yi, Ming Zhang, Ming-Qing Xu, Department of Liver Surgery, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Ji-Tong Zhao, Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Author contributions: Yi PS drafted the article; Zhang M designed the study; Zhao JT analyzed and interpreted the data; Xu MQ approved the final version to be submitted; Yi PS and Zhang M contributed equally to this work.
Conflict-of-interest statement: No conflict of interests is declared by the authors.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Ming-Qing Xu, MD, Department of Liver Surgery, West China Hospital, Sichuan University, Guoxue Road, Chengdu 610041, Sichuan Province, China. xumingqing0018@163.com
Telephone: +86-28-85422870 Fax: +86-28-85422870
Received: January 22, 2016 Peer-review started: January 22, 2016 First decision: March 1, 2016 Revised: March 14, 2016 Accepted: April 21, 2016 Article in press: April 22, 2016 Published online: May 18, 2016 Processing time: 111 Days and 14.1 Hours
Core Tip
Core tip: Trans-catheter arterial chemoembolization (TACE) is recommended as the standard treatment of intermediate hepatocellular carcinoma (HCC) by the Barcelona Clinic Liver Cancer guideline, and this review investigates whether liver resection is better than TACE for intermediate HCC. Based on published studies, we compare the survival benefits and complications of liver resection and TACE for intermediate HCC. We also compare the survival benefits of liver resection in early and intermediate HCC. We find that liver resection could achieve better or at least comparable survival outcomes compared with TACE for intermediate HCC; however, we do not observe a significant difference between liver resection and TACE in terms of safety and morbidity.
